Sep 25, 2023, 18:53 PM by

Optibrium, a leading developer of software and AI solutions for drug discovery, today launched the latest version of its drug discovery platform, StarDrop 7.5, introducing a powerful module for drug metabolism prediction.

Sep 25, 2023, 18:53 PM by

Bio-IT World Europe will convene in London 29-30 November 2023 to foster collaboration among the UK and Europe's biopharma and technology leaders who are forging new frontiers in precision medicine.

Sep 25, 2023, 08:55 AM by

Sep 25, 2023, 08:55 AM by

Sep 25, 2023, 08:55 AM by

Sep 25, 2023, 08:55 AM by

Sep 25, 2023, 08:55 AM by

Sep 25, 2023, 08:55 AM by

MAVERICK is a Raman-based PAT solution that requires no complex modeling. It is an optical in-line analyzer that provides real-time monitoring and control of glucose, lactate, and total biomass in mammalian cell cultures, in addition to rich process fingerprint data to support large-scale efforts in predictive bioprocess modeling. MAVERICK is also the first turn-key device to utilize Raman spectroscopy for bioprocess control, with no modeling and development required. With its in-line optical sampling probe, biopharmaceutical scientists and engineers can quickly develop their cell culture media and design feeding and control strategies.

Sep 22, 2023, 08:33 AM by

Sep 22, 2023, 08:33 AM by

Health Plan of San Joaquin (HPSJ) just announced they selected ZeOmega’s care management solution to support the complex health needs of 450,000+ Medi-Cal members and promote equitable care statewide. HPSJ will use ZeOmega’s platform to consolidate and analyze members’ health data to produce insights informing care needs. The partnership will empower HPSJ to support members’ physical, mental, and behavioral health needs and align with CalAIM’s whole-person approach to healthcare.

Sep 22, 2023, 08:33 AM by

Mirikizumab is the first IL-23p19 targeted biologic recommended by NICE for use within NHS England and Wales for treating moderately to severely active ulcerative colitis in adults.1,2. In two randomised, double-blind, placebo-controlled phase 3 trials, LUCENT-1 and LUCENT-2, mirikizumab achieved primary and key secondary endpoints, including sustained clinical remission. Decreases in bowel urgency severity were observed as early as week 2 in patients treated with mirikizumab versus placebo in LUCENT-1.2 Mirikizumab has been recommended through the NICE cost-comparison process meaning NHS England and commissioning groups have agreed to provide funding to implement this guidance within 30 days from publication of the technology appraisal guidance (TAG) rather than the standard 90 days, providing faster access to a new treatment option for eligible adults living with moderately to severely active ulcerative colitis1

Sep 22, 2023, 08:33 AM by

Sep 22, 2023, 08:33 AM by

Sep 21, 2023, 08:26 AM by

Assessment is the Latest Industry Recognition of the Value ResultsCX Delivers Through its End-to-End CX Solutions

Sep 21, 2023, 08:26 AM by

Kalderos names veteran healthcare leader Angie Franks as new CEO

Sep 21, 2023, 08:26 AM by

Integrated DNA Technologies will sell Aldevron cGMP-manufactured CRISPR nucleases to enable customers to rapidly transition from discovery to clinic.

Sep 21, 2023, 01:00 AM by User Not Found

Bio-IT World | Over 900 genes have been implicated in the resistance of tumors to platinum-based chemotherapy that map to many different cellular pathways, thwarting efforts to identify a biomarker to predict refractoriness.

Sep 20, 2023, 08:47 AM by

Mural Health Raises $8M Led by Bessemer Venture Partners to Accelerate Growth Funding enables Mural Health to expand its Mural Link platform to modernize the clinical trial participant experience

Sep 20, 2023, 08:47 AM by

AVIA's newest AI-focused initiative aims to share practical application of AI to better inform - and transform - the healthcare industry

Sep 20, 2023, 08:47 AM by

This presentation will offer practical strategies to achieve definitive results when researching unstable, sticky, or insoluble compounds.